{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:06:27Z","timestamp":1791083187070,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T00:00:00Z","timestamp":1672099200000},"content-version":"vor","delay-in-days":148,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1002\/rth2.12795","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T08:36:04Z","timestamp":1663662964000},"page":"e12795","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Alteplase or tenecteplase for thrombolysis in ischemic stroke: An illustrated review"],"prefix":"10.1016","volume":"6","author":[{"given":"Annie","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phavalan","family":"Rajendram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelagh B.","family":"Coutts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7276-9551","authenticated-orcid":false,"given":"Amy Y.X.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1002\/rth2.12795_bb0010","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(21)00252-0","article-title":"Global, regional, and national burden of stroke and its risk factors, 1990\u20102019: a systematic analysis for the global burden of disease study 2019","volume":"20","year":"2021","journal-title":"Lancet Neurol"},{"issue":"18","key":"10.1002\/rth2.12795_bb0015","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1001\/jama.2021.5469","article-title":"The leading causes of death in the US for 2020","volume":"325","author":"Ahmad","year":"2021","journal-title":"JAMA"},{"issue":"8","key":"10.1002\/rth2.12795_bb0020","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","article-title":"Heart disease and stroke Statistics\u20102021 update: a report from the American Heart Association","volume":"143","author":"Virani","year":"2021","journal-title":"Circulation"},{"issue":"24","key":"10.1002\/rth2.12795_bb0025","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","article-title":"Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt\u2010PA stroke study group","volume":"333","year":"1995","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1002\/rth2.12795_bb0030","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa0804656","article-title":"Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke","volume":"359","author":"Hacke","year":"2008","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1002\/rth2.12795_bb0035","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1177\/1747493018790024","article-title":"Tenecteplase for the treatment of acute ischemic stroke: a review of completed and ongoing randomized controlled trials","volume":"13","author":"Coutts","year":"2018","journal-title":"Int J Stroke"},{"issue":"10262","key":"10.1002\/rth2.12795_bb0040","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S0140-6736(20)32163-2","article-title":"Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta\u2010analysis of individual patient data","volume":"396","author":"Thomalla","year":"2020","journal-title":"Lancet"},{"issue":"10029","key":"10.1002\/rth2.12795_bb0045","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/S0140-6736(16)00163-X","article-title":"Endovascular thrombectomy after large\u2010vessel ischaemic stroke: a meta\u2010analysis of individual patient data from five randomised trials","volume":"387","author":"Goyal","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/rth2.12795_bb0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1706442","article-title":"Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct","volume":"378","author":"Nogueira","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1002\/rth2.12795_bb0055","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1056\/NEJMoa1713973","article-title":"Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging","volume":"378","author":"Albers","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12795_bb0060","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/107602960200800401","article-title":"Thrombolytic therapy","volume":"8","author":"Baker","year":"2002","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1002\/rth2.12795_bb0065","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2141.2005.05444.x","article-title":"Molecular mechanisms of fibrinolysis","volume":"129","author":"Cesarman\u2010Maus","year":"2005","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1002\/rth2.12795_bb0070","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00415-013-7102-0","article-title":"Intravenous tenecteplase in acute ischemic stroke: an updated review","volume":"261","author":"Behrouz","year":"2014","journal-title":"J Neurol"},{"issue":"15","key":"10.1002\/rth2.12795_bb0075","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.2165\/00003088-200241150-00001","article-title":"Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction","volume":"41","author":"Tanswell","year":"2002","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"10.1002\/rth2.12795_bb0080","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1073\/pnas.91.9.3670","article-title":"A faster\u2010acting and more potent form of tissue plasminogen activator","volume":"91","author":"Keyt","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1002\/rth2.12795_bb0085","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/protein\/6.5.529","article-title":"Making tissue\u2010type plasminogen activator more fibrin specific","volume":"6","author":"Paoni","year":"1993","journal-title":"Protein Eng"},{"issue":"7","key":"10.1002\/rth2.12795_bb0090","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/S0149-2918(01)80086-2","article-title":"Tenecteplase: a review","volume":"23","author":"Davydov","year":"2001","journal-title":"Clin Ther"},{"issue":"5","key":"10.1002\/rth2.12795_bb0095","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1177\/1747493016641112","article-title":"Tenecteplase versus alteplase in stroke thrombolysis: an individual patient data meta\u2010analysis of randomized controlled trials","volume":"11","author":"Huang","year":"2016","journal-title":"Int J Stroke"},{"issue":"12","key":"10.1002\/rth2.12795_bb0100","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1161\/STROKEAHA.115.011290","article-title":"Coagulation and fibrinolytic activity of tenecteplase and alteplase in acute ischemic stroke","volume":"46","author":"Huang","year":"2015","journal-title":"Stroke"},{"key":"10.1002\/rth2.12795_bb0105","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1474-4422(17)30253-3","article-title":"Tenecteplase versus alteplase for management of acute ischaemic stroke (nor\u2010test): a phase 3, randomised, open\u2010label, blinded endpoint trial","volume":"16","author":"Logallo","year":"2017","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1002\/rth2.12795_bb0110","first-page":"207","article-title":"A review of available fibrin\u2010specific thrombolytic agents used in acute myocardial infarction. Pharmacotherapy: the journal of human pharmacology and drug","volume":"21","author":"Tsikouris","year":"2001","journal-title":"Therapy"},{"key":"10.1002\/rth2.12795_bb0115","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1161\/STROKEAHA.118.022606","volume":"50","author":"Powers","year":"2019","journal-title":"Stroke"},{"key":"10.1002\/rth2.12795_bb0120","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1177\/1747493018786616","article-title":"Canadian stroke best practice recommendations for acute stroke management: prehospital, emergency department, and acute inpatient stroke care, 6th edition, update 2018","volume":"13","author":"Boulanger","year":"2018","journal-title":"Int J Stroke"},{"key":"10.1002\/rth2.12795_bb0125","doi-asserted-by":"crossref","first-page":"I","DOI":"10.1177\/2396987321989865","article-title":"European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke","volume":"6","author":"Berge","year":"2021","journal-title":"Eur Stroke J"},{"key":"10.1002\/rth2.12795_bb0130","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.04.001","article-title":"Guidelines for the intravenous application of recombinant tissue\u2010type plasminogen activator (alteplase), the second edition, october 2012: a guideline from the Japan Stroke Society","volume":"22","author":"Minematsu","year":"2013","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1002\/rth2.12795_bb0135","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/01.STR.0000227191.01792.e3","article-title":"Alteplase at 0.6 mg\/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J\u2010ACT)","volume":"37","author":"Yamaguchi","year":"2006","journal-title":"Stroke"},{"key":"10.1002\/rth2.12795_bb0140","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1161\/STROKEAHA.109.573477","article-title":"Effects of 0.6 mg\/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion: Japan Alteplase Clinical Trial II (J\u2010ACT II)","volume":"41","author":"Mori","year":"2010","journal-title":"Stroke"},{"key":"10.1002\/rth2.12795_bb0145","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1161\/STROKEAHA.110.589606","article-title":"Thrombolysis with 0.6 mg\/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post\u2010marketing alteplase registration study (J\u2010MARS)","volume":"41","author":"Nakagawara","year":"2010","journal-title":"Stroke"},{"key":"10.1002\/rth2.12795_bb0150","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1161\/STROKEAHA.109.562991","article-title":"Routine use of intravenous low\u2010dose recombinant tissue plasminogen activator in japanese patients: general outcomes and prognostic factors from the samurai register","volume":"40","author":"Toyoda","year":"2009","journal-title":"Stroke"},{"key":"10.1002\/rth2.12795_bb0155","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1161\/STROKEAHA.109.572040","article-title":"Phase IIB\/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial","volume":"41","author":"Haley","year":"2010","journal-title":"Stroke"},{"key":"10.1002\/rth2.12795_bb0160","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1161\/01.STR.0000154872.73240.e9","article-title":"A pilot dose\u2010escalation safety study of tenecteplase in acute ischemic stroke","volume":"36","author":"Haley","year":"2005","journal-title":"Stroke"},{"key":"10.1002\/rth2.12795_bb0165","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1161\/STROKEAHA.114.008504","article-title":"Tenecteplase\u2010tissue\u2010type plasminogen activator evaluation for minor ischemic stroke with proven occlusion","volume":"46","author":"Coutts","year":"2015","journal-title":"Stroke"},{"key":"10.1002\/rth2.12795_bb0170","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/1747493019879652","article-title":"Determining the optimal dose of tenecteplase before endovascular therapy for ischemic stroke (EXTEND\u2010IA TNK Part 2): a multicenter, randomized, controlled study","volume":"15","author":"Campbell","year":"2020","journal-title":"Int J Stroke"},{"key":"10.1002\/rth2.12795_bb0175","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa1109842","article-title":"A randomized trial of tenecteplase versus alteplase for acute ischemic stroke","volume":"366","author":"Parsons","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12795_bb0180","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S1474-4422(15)70017-7","article-title":"Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open\u2010label, blinded endpoint study","volume":"14","author":"Huang","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1002\/rth2.12795_bb0185","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1056\/NEJMoa1716405","article-title":"Tenecteplase versus alteplase before thrombectomy for ischemic stroke","volume":"378","author":"Campbell","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12795_bb0190","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1001\/jama.2018.12498","article-title":"Association of clinical, imaging, and thrombus characteristics with recanalization of visible intracranial occlusion in patients with acute ischemic stroke","volume":"320","author":"Menon","year":"2018","journal-title":"JAMA"},{"key":"10.1002\/rth2.12795_bb0195","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1161\/STROKEAHA.110.609693","article-title":"The importance of size: successful recanalization by intrave\u2010nous thrombolysis in acute anterior stroke depends on thrombus length","volume":"42","author":"Riedel","year":"2011","journal-title":"Stroke"},{"key":"10.1002\/rth2.12795_bb0200","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1552-6569.2012.00761.x","article-title":"Measurement of length of hyperdense MCA sign in acute ischemic stroke predicts disappearance after IV tPA","volume":"24","author":"Shobha","year":"2014","journal-title":"J Neuroimaging"},{"key":"10.1002\/rth2.12795_bb0205","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2001123","article-title":"Endovascular thrombectomy with or without intravenous alteplase in acute stroke","volume":"382","author":"Yang","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12795_bb0210","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1001\/jama.2020.23522","article-title":"Effect of mechanical thrombectomy without vs with intravenous thrombolysis on functional outcome among patients with acute ischemic stroke: the skip randomized clinical trial","volume":"325","author":"Suzuki","year":"2021","journal-title":"JAMA"},{"key":"10.1002\/rth2.12795_bb0215","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jama.2020.23523","article-title":"Effect of endovascular treatment alone vs intravenous alteplase plus endovascular treatment on functional independence in patients with acute ischemic stroke: the DEVT randomized clinical trial","volume":"325","author":"Zi","year":"2021","journal-title":"JAMA"},{"key":"10.1002\/rth2.12795_bb0220","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1056\/NEJMoa2107727","article-title":"A randomized trial of intravenous alteplase before endovascular treatment for stroke","volume":"385","author":"LeCouffe","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1002\/rth2.12795_bb0225","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S1474-4422(22)00171-5","article-title":"Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile stroke unit (TASTE\u2010A): a phase 2, randomised, open\u2010label trial","volume":"21","author":"Bivard","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1002\/rth2.12795_bb0230","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(22)01054-6","article-title":"Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open\u2010label, registry\u2010linked, randomised, controlled, non\u2010inferiority trial","volume":"400","author":"Menon","year":"2022","journal-title":"Lancet"},{"key":"10.1002\/rth2.12795_bb0235","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jama.2020.1511","article-title":"Effect of intravenous tenecteplase dose on cerebral reperfusion before thrombectomy in patients with large vessel occlusion ischemic stroke: the EXTEND\u2010IA TNK Part 2 randomized clinical trial","volume":"323","author":"Campbell","year":"2020","journal-title":"JAMA"},{"key":"10.1002\/rth2.12795_bb0240","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S1474-4422(22)00124-7","article-title":"Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR\u2010TEST 2, Part A): a phase 3, randomised, open\u2010label, blinded endpoint, non\u2010inferiority trial","volume":"21","author":"Kvistad","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1002\/rth2.12795_bb0245","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1212\/01.wnl.0000344168.05315.9d","article-title":"Acute ischemic stroke: imaging\u2010guided tenecteplase treatment in an extended time window","volume":"72","author":"Parsons","year":"2009","journal-title":"Neurology"},{"key":"10.1002\/rth2.12795_bb0250","unstructured":"Stroke Foundation. Clinical guidelines for stroke management 2017. (Chapter 3 of 8: Acute medical and surgical management). Melbourne Australia. 2021. Available from: informme.org.au\/Guidelines\/Clinical\u2010Guidelines\u2010for\u2010Stroke\u2010Management. Accessed September 5, 2022."},{"issue":"11","key":"10.1002\/rth2.12795_bb0255","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1161\/01.STR.28.11.2109","article-title":"Intracerebral hemorrhage after intravenous t\u2010PA therapy for ischemic stroke","volume":"28","year":"1997","journal-title":"Stroke"},{"issue":"1","key":"10.1002\/rth2.12795_bb0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000103110","article-title":"Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors","volume":"24","author":"Lansberg","year":"2007","journal-title":"Cerebrovasc Dis"},{"key":"10.1002\/rth2.12795_bb0265","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1161\/STR.0000000000000152","article-title":"Treatment and outcome of hemorrhagic transformation after intravenous alteplase in acute ischemic stroke: a scientific statement for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"48","author":"Yaghi","year":"2017","journal-title":"Stroke"},{"issue":"3","key":"10.1002\/rth2.12795_bb0270","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1161\/STROKEAHA.120.030859","article-title":"Routine use of Tenecteplase for thrombolysis in acute ischemic stroke","volume":"52","author":"Zhong","year":"2021","journal-title":"Stroke"},{"issue":"9558","key":"10.1002\/rth2.12795_bb0275","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0140-6736(07)60149-4","article-title":"Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in stroke\u2010monitoring study (SITS\u2010MOST): an observational study","volume":"369","author":"Wahlgren","year":"2007","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/rth2.12795_bb0280","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.annemergmed.2016.02.019","article-title":"A novel approach to the treatment of orolingual angioedema after tissue plasminogen activator administration","volume":"68","author":"Pahs","year":"2016","journal-title":"Ann Emerg Med"},{"key":"10.1002\/rth2.12795_bb0285","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/practneurol-2018-002189","article-title":"Hypersensitivity reactions to recombinant tissue plasminogen activator","volume":"20","author":"Alakbarzade","year":"2020","journal-title":"Pract Neurol"},{"key":"10.1002\/rth2.12795_bb0290","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/1941874415587680","article-title":"Management of postthrombolysis hemorrhagic and orolingual angioedema complications","volume":"5","author":"O'Carroll","year":"2015","journal-title":"Neurohospitalist"},{"issue":"9","key":"10.1002\/rth2.12795_bb0295","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1212\/01.WNL.0000058840.66596.1A","article-title":"Hemi\u2010orolingual angioedema and ACE inhibition after alteplase treatment of stroke","volume":"60","author":"Hill","year":"2003","journal-title":"Neurology"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rth2.12795","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/rth2.12795","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922023561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037922023561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rth2.12795","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:23:34Z","timestamp":1762863814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037922023561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S2475037922023561"],"URL":"https:\/\/doi.org\/10.1002\/rth2.12795","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alteplase or tenecteplase for thrombolysis in ischemic stroke: An illustrated review","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1002\/rth2.12795","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The Authors. Research and Practice in Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis (ISTH)","name":"copyright","label":"Copyright"}],"article-number":"e12795"}}